Tuesday, 25 November 2014

Biomarkers in inflammatory disease. Speaker Dr Mary Keir Monday 1st December.

 

 

 

 

 

 

 

 

Speaker: Dr Mary Keir PhD, Genetech Inc, South San Francisco

 

Venue: L2.6, 2ND Floor, William Leech Building, Medical School

Date and time: Monday 1st December 2014 at 1.00pm

 

Dr Mary Keir will present

 

“Predictive biomarkers for response to etrolizumab therapy in IBD”

 

Biog: Mary Keir received her Ph.D. in Biomedical Sciences at the University of California, San Francisco, where her thesis work focused on innate responses to HIV infection in the human thymus. Following completion of her Ph.D, she undertook postdoctoral training at Harvard Medical School, where she studied the role of PD-1:PD-L1 interactions in T cell tolerance and autoimmunity. Mary next moved to Genentech to join the Immunology Diagnostic Discovery group and focus on biomarker identification and utility in clinical trials. At Genentech, she has led biomarker efforts in both systemic lupus erythematosus and inflammatory bowel disease (IBD). Her current research focus is on predictive biomarkers of inflammatory subgroups in IBD as well as prognostic biomarkers of disease.

 

 

 

Jenna Ho

PA to:

Professor John Isaacs, Director of the Institute of Cellular Medicine

Professor Neil Sheerin, Professor of Nephrology

4th Floor William Leech Building

Medical School

Newcastle University

Framlington Place

Newcastle Upon Tyne

NE2 4HH

 

Tel: 0191 208 6227

Fax: 0191 208 5066

 

Email: jenna.ho@newcastle.ac.uk

Web:    http://www.ncl.ac.uk/

 

No comments:

Post a comment

Note: only a member of this blog may post a comment.